M. Schiestl, M. Zabransky, and F. Sörgel, Ten years of biosimilars in Europe: development and evolution of the regulatory pathways, Drug Des. Devel. Ther, vol.11, p.1509, 2017.

A. Berghout, Clinical programs in the development of similar biotherapeutic products: Rationale and general principles, Biologicals, vol.39, pp.293-296, 2011.

, uri=LEGISSUM:l14527&from=FR%20La%20directive%20de%20 l%E2%80%99Union%20europ%C3%A9enne%20%E2%80%93%20derni%C3%A8re%20mo dification%2030.08.2015. (Accessed, p.6, 2018.

, Eprex_Public Assessment Report_product information.pdf, p.6, 2018.

, Epoetin alfa hexal_European Public Assessment Report_product information.pdf, p.6, 2018.

, Lantus_ European Public Assessment Report _product-information.pdf, p.6, 2018.

, Abasaglar-previously-Abasria_ European Public Assessment Report _product information.pdf. (Accessed, p.6, 2018.

, Remicade_ European Public Assessment Report _product information.pdf, p.6, 2018.

, Remsima_ European Public Assessment Report _product information.pdf, p.6, 2018.

, Biosimilars in the EU. Information guide for healthcare professionals, European Medicines Agency (EMA), 2017.

, Les Biosimilaires en 15 questions -Claude Lepen -2014

, Committee for Medicinal Products for Human (CHMP)European Medicines Agency (EMA), Committee for Medicinal Products for Human (CHMP), European Medicines Agency (EMA), 2014.

C. European-medicines-agency, M. P. For, and H. , Guideline on similar biological medicinal products containing biotechnology-derived proteins as active substance: quality issues. Lond, Eur. Med. Agency, vol.14, 2017.

, Guideline on immunogenicity assessment of monoclonal antibodies intended for in vivo clinical use, European Medicines Agency (EMA), 2012.

, Guideline on development, production, characterisation and specifications for monoclonal antibodies and related products, European Medicines Agency (EMA), 2008.

, Committee for Medicinal Products for Human (CHMP), European Medicines Agency (EMA), 2006.

, ICH Topic Q6B Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products, European Medicines Agency (EMA), 1999.

. Ich and . Ich, Harmonised Tripartite Guideline validation of analytical procedures: Text and Methodology Q2(R1). Current Step 4 version, 2005.

. Ich and . Ich, Harmonised Tripartite Guideline Stability testing of new drug substances and products Q1A(R2), 2003.

. Ich and . Ich, Topic Q5C Quality of Biotechnological Products: Stability Testing of Biotechnological/Biological Products, 1996.

, Note for guidance on in-use stability testing of human medicinal products, European Medicines Agency (EMA), 2001.

, ICH Topic Q5E -Comparability of Biotechnological/Biological Products NOTE FOR GUIDANCE ON BIOTECHNOLOGICAL/BIOLOGICAL PRODUCTS SUBJECT TO CHANGES IN THEIR MANUFACTURING PROCESS, European Medicines Agency (EMA), 2005.

, Questions and Answers -Refusal of the marketing authorisation for Solumarv (insulin human), EMA Lond, 2015.

, Guideline on similar biological medicinal products containing biotechnologyderived proteins as active substance: non-clinical and clinical issues, European Medicines Agency (EMA), 2014.

C. European-medicines-agency, M. P. For, and H. , Guideline on similar biological medicinal products containing monoclonal antibodies: non-clinical and clinical issues, Eur. Med. Agency, 2012.

, ICH guideline S6(R1) -Preclinical safety evaluation of biotechnology-derived pharmaceuticals, European Medicines Agency (EMA), 2011.

. Ich and . Ich, Harmonised Tripartite Guideline Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals S6(R1), 2011.

, Guideline on the environmental risk assessment of medicinal products for human use, European Medicines Agency (EMA), 2006.

, Questions and answers on 'Guideline on the environmental risk assessment of medicinal products for human use, European Medicines Agency (EMA), 2016.

, Guideline on the choice of the non-inferiority margin, European Medicines Agency (EMA), 2005.

, Committee for Medicinal Products for Human (CHMP). ICH Topic E8 -General Considerations for, European Medicines Agency (EMA), 1998.

, Guideline on the clinical investgation of the pharmacokinetics of therapeutic proteins, European Medicines Agency (EMA), 2007.

, Committee for Medicinal Products for Human (CHMP), European Medicines Agency (EMA), 2010.

, Committee for Medicinal Products for Human (CHMP), European Medicines Agency (EMA), 2011.

, Commission Européenne. Communication from the Commission -Guideline on the format and content of applications for agreement or modification of a paediatric investigation plan and requests for waivers or deferrals and concerning the operation of the compliance check and on criteria for assessing significant studies Text with EEA relevance, décembre 2006 relatif aux médicaments à usage pédiatrique, vol.726, p.38, 1901.

, Guideline on good pharmacovigilance practices (GVP) Module V -Risk management systems (Rev 2), EMA Lond, 2017.

, ANSM. Bonnes pratiques de pharmacovigilance, 2018.

N. Scholz, Medicinal products in the European Union, Eur. Parliam. Res. Serv, 2015.

A. Qu, est ce qu'un médicament générique ? -ANSM : Agence nationale de sécurité du médicament et des produits de santé, p.6, 2018.

, Accessed: 6th October 2018) 44. Federal Institute for Drugs and Medical Devices. PUBLIC ASSESSMENT REPORTDecentralised Procedure -Teriparatid-ratiopharm 20 ?g / 80ml, Solution for injection, LEEM. Quels sont les enjeux liés à la propriété industrielle, 2017.